ASXDimerix Receives US$10M Upfront Payment from Everest
other announcement
Dimerix (DXB) News
Latest articles and price-sensitive announcements with AI sentiment classification.
Dimerix Assumes Sponsorship of US IND for New Asset DMX-652
other announcement
Dimerix Quarterly Activities Report and Appendix 4C
other announcement
StockheadLong Shortz with Dimerix: Expanding the Kidney disease pipeline
How does DMX-652 complement the late-stage DMX-200 program and what are the key clinical and commercial milestones ahead. ... Read More The post Long Shortz with Dimerix: Expanding the Kidney disease pipeline appeared first on Stockhead.
Dimerix to Present at TechKnow Invest Conference 2026
other announcement
Biocurious: In its quest for the “perfect” kidney drug candidate, Dimerix won’t let the grass grow under its feet
Having run the ruler over 140 acquisition proposals, Dimerix has settled on a drug program targeting heart surgery related kidney ... Read More The post Biocurious: In its quest for the “perfect” kidney drug candidate, Dimerix won’t let the grass grow under its feet appeared first on Stockhead.
Dimerix lands $10m loan for DMX-200 Phase 3 trial, acquires new asset
the $10 million loan facility funds completion of the Phase 3 ACTION3 trial for DMX-200. ... Read More The post Dimerix lands $10m loan for DMX-200 Phase 3 trial, acquires new asset appeared first on Stockhead.
Google NewsDimerix Limited (ASX:DXB) Shares Rise 4.17% Intraday as the DMX-200 Kidney Story Gathers Momentum - Kalkine
Dimerix Limited (ASX:DXB) Shares Rise 4.17% Intraday as the DMX-200 Kidney Story Gathers Momentum Kalkine
Small CapsDimerix Expands Pipeline with Acquisition of Phase 2 Asset
takeover announcement
Dimerix Non-Dilutive Funding Builds Pipeline, Boosts Runway
other announcement
KalkineDimerix (ASX:DXB): Why Is It Back on the Penny Stock Radar?
Highlights Dimerix is returning to focus as clinical milestones become the clearest measure of progress across its kidney disease program. Funding discipline, trial execution and risk control are shaping how the companys biotechnology story is being assessed. Penny-stock coverage is narrowing towards measurable evidence, balance sheet resilience and careful use of financial resources. Australian shares have opened with a cautious and selective tone as oil volatility, steadier banking acti...
Dimerix to provide kidney disease candidate access through post-trial pathways
Post-trial access is intended to support continued access to DMX-200 for patients with rare kidney disease focal segmental glomerular sclerosis. ... Read More The post Dimerix to provide kidney disease candidate access through post-trial pathways appeared first on Stockhead.
DMX-200 Available To Patients Via Post-Trial Access Pathways
other announcement
Why Dimerix (ASX:DXB) Shares Are Back on the Radar - Kalkine
Why Dimerix (ASX:DXB) Shares Are Back on the Radar Kalkine
Dimerix (ASX:DXB): Biotech Stock Pullback Puts Clinical Trial Watchers on Alert - Kalkine
Dimerix (ASX:DXB): Biotech Stock Pullback Puts Clinical Trial Watchers on Alert Kalkine
Dimerix (ASX: DXB) Explodes Higher as Biotech Traders Chase Momentum - Kalkine
Dimerix (ASX: DXB) Explodes Higher as Biotech Traders Chase Momentum Kalkine
Dimerix inks Asian licensing deal worth up to $480 million for kidney disease drug
In a deal worth up to circa $480 million, Dimerix has signed an exclusive Asian licensing agreement for its rare ... Read More The post Dimerix inks Asian licensing deal worth up to $480 million for kidney disease drug appeared first on Stockhead.
Dimerix (ASX:DXB) Shares Rally After Unlocking New Commercial Opportunity for DMX-200 - Kalkine
Dimerix (ASX:DXB) Shares Rally After Unlocking New Commercial Opportunity for DMX-200 Kalkine
Dimerix Licenses DMX200 to Everest for China and Asia Region
other announcement
Dimerix Quarterly Activities Report and Appendix 4C
other announcement
Why Is (ASX:DXB) Dimerix Advancing Its Phase 3 Strategy?
Highlights Phase 3 pathway gains stronger clarity Trial design aligned with regulators Program momentum remains steady Dimerix continues to refine its late-stage kidney disease program, strengthening clinical confidence and aligning with regulatory expectations while progressing toward a decisive trial outcome. The biotech landscape often shifts on subtle developments rather than headline-grabbing breakthroughs. One such example is Dimerix Ltd (ASX:DXB), which has recently taken a measu...
Shares In Dimerix (ASX:DXB) Fell 35% Today; Not About The Data, But About the Timing - Stocks Down Under
Shares In Dimerix (ASX:DXB) Fell 35% Today; Not About The Data, But About the Timing Stocks Down Under
Dimerix Releases Investor Presentation and Video Recording
other announcement
Dimerix to conduct blinded review of phase III kidney disease trial data
Dimerix to conduct blinded review of ACTION3 data later this month to confirm statistical assumptions for primary endpoint ... Read More The post Dimerix to conduct blinded review of phase III kidney disease trial data appeared first on Stockhead.
Dimerix Presents at Euroz Hartleys Institutional Conference
other announcement
Dimerix to Conduct Review of ACTION3 Statistical Assumptions
other announcement
Dimerix doses final patient in Phase III kidney disease trial as enrolment exceeds target
Dimerix’s ACTION3 study DMX-200 in focal segmental glomerulosclerosis doses final adult patient with 333 patients recruited ... Read More The post Dimerix doses final patient in Phase III kidney disease trial as enrolment exceeds target appeared first on Stockhead.
Dimerix Phase 3 Trial Last Patient Receives First Dose
other announcement
Dimerix Invitation to Perth and Singapore Investor Briefings
other announcement
Dimerix Presents at Oppenheimer Life Sciences Conference
other announcement
Dimerix to Present at Euroz Hartleys Healthcare Forum 2026
other announcement
Clinical trial update at J.P. Morgan Healthcare Conference
other announcement
Dimerix receives input from FDA on ACTION3 trial endpoints
other announcement
BioMarin to acquire Dimerix US Partner, Amicus Therapeutics
other announcement
DMX-200 ACTION3 Phase 3 Trial Completes Recruitment
other announcement
Change of Director's Interest Notice - CS,HA,NW,SP & MD
director_dealing announcement
Notification regarding unquoted securities - DXB
other announcement
Canaccord Drug & Device Conference Investor Presentation
other announcement
2025 AGM Notice of Meeting, Letter of Access and Proxy
other announcement
Successful PARASOL Collaboration Data Analysis Outcome
other announcement
DMX-200 receives Orphan Drug Designation in Japan
other announcement